echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > NEJM: Hydrocortisone treatment started 2 weeks after birth does not significantly improve survival without moderate to severe bronchopulmonary dysplasia in premature infants

    NEJM: Hydrocortisone treatment started 2 weeks after birth does not significantly improve survival without moderate to severe bronchopulmonary dysplasia in premature infants

    • Last Update: 2022-04-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Bronchopulmonary dysplasia is prevalent in very preterm infants, accounting for approximately 50% of surviving infants, and preterm birth, mechanical ventilation, oxygen exposure, and inflammation are important factors in bronchopulmonary dysplasia in preterm infants


    We investigated the effects of hydrocortisone treatment on lung development, neurodevelopment, and survival in preterm infants with bronchopulmonary dysplasia after the second week of life



    Differences in efficacy and safety endpoints between groups

    Differences in efficacy and safety endpoints between groups

    In preterm infants with bronchopulmonary dysplasia , treatment with hydrocortisone from days 14 to 28 did not improve survival without moderate to severe bronchopulmonary dysplasia, nor did 2-year neurodevelopmental outcomes between groups Significant difference


    In preterm infants with bronchopulmonary dysplasia, treatment with hydrocortisone starting from postnatal days 14 to 28 did not improve survival without moderate to severe bronchopulmonary dysplasia, nor did the 2-year neurodevelopmental outcomes differ significantly between groups
    .
    In preterm infants with bronchopulmonary dysplasia, treatment with hydrocortisone starting from postnatal days 14 to 28 did not improve survival without moderate to severe bronchopulmonary dysplasia, nor did the 2-year neurodevelopmental outcomes differ significantly between groups
    .

    Original Source:
    Hydrocortisone to Improve Survival without Bronchopulmonary Dysplasia.


    Leave a comment here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.